Niagen acquires QUB NR patent portfolio; $1M upfront, annual payments through 2038

Niagen Bioscience, Inc.

One-time ~$1M payment to QUB for accrued royalties through 2024; annual $500K+£35K through 2038.
Additional one-time payments of $1.5M in 2035 and $2M in 2038 as consideration for patent assignment and release.
QUB assigned all patent rights to ChromaDex; prior JOMA and License Agreement terminated with royalty obligations released.
Acquired portfolio includes composition-of-matter patents for NR salt forms (e.g., NR Malate, NR Tartrate) and global rights.
Niagen now sole owner of core NR IP estate with >90 patents worldwide; CEO cites enhanced control and shareholder protection.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.